H.C. Wainwright analyst Andrew Fein maintained a Buy rating on ProQR (NASDAQ: PRQR) today and set a price target of $20. The company’s shares closed yesterday at $17.01.
Fein noted:
“Our price target of $20/share is based on an equally-weighted composite of: (a) $18.0/ share, as a 25x multiple of taxed and diluted $9.92 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.9/ share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.3% and a 43.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
ProQR has an analyst consensus of Strong Buy, with a price target consensus of $25.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $22.85 and a one-year low of $2.75. Currently, ProQR has an average volume of 446.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis.
